ArticleAbdominal radiology (New York)2026
MRI-based multiregional radiomics for pretreatment prediction of pathologic complete response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: a bicenter study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aims to compare, select, and investigate MRI-based multiregional radiomics model to predict pathologic complete response (pCR) in Locally advanced rectal cancer (LARC) patients after neoadjuvant chemoradiotherapy (nCRT).
methodsThis retrospective study included 245 patients who underwent rectal MRI examination before nCRT were recruited and split into training (hospital 1, n = 177) and external validation cohort (hospital 2, n = 68). Pretreatment T2WI and ADC images were used to manually delineate volumetric region of interest. Intratumoral, peritumoral-2 mm, peritumoral-3 mm, peritumoral-5 mm, and peritumoral-mesorectal fat (MRF) radiomics features were extracted. Clinical model was built based on clinical and MRI features. Diagnosis performance was compared among models. 3-year recurrence-free survival (RFS) was evaluated by Kaplan-Meier curve.
resultscN stage (odds ratio = 2.62, 95%CI,1.13-6.11) was a risk factor to construct clinical model. Peritumoral-3 mm radiomics model showed slightly higher performance than peritumoral-2 mm, peritumoral-5 mm, and peritumoral-MRF radiomics model, but there were no significant differences (all P > 0.05). Combining T2WI and ADC based intratumoral and peritumoral-3 mm radiomics model showed good performance with AUC of 0.793 and 0.759 in training and external validation cohort, respectively. The clinical-radiomics combined model showed better performance than clinical model (AUC, 0.829 vs. 0.599; P < 0.001) and better performance to the intratumoral and peritumoral-3 mm radiomics model (AUC, 0.829 vs. 0.793; P = 0.04) in training cohort. And the clinical-radiomics combined model showed better performance than clinical model (AUC, 0.793 vs. 0.599; P < 0.001) and better performance to the intratumoral and peritumoral-3 mm radiomics model (AUC, 0.795 vs. 0.759; P = 0.21) in external validation cohort. Kaplan-Meier survival curves showed high-risk patients defined by nomogram based non-pCR had a worse 3-year RFS than that of low-risk patients.
conclusionThe nomogram integrating T2WI and ADC based intratumoral and peritumoral radiomics signatures and cN stage could preoperative predict pCR. The nomogram based pCR was associated with 3-year RFS.
Indexed as
Identifiers
41186718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.